$21.23−0.15 (−0.70%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Amneal Pharmaceuticals (AMRX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~9.6%/yr (FY21→FY25), net margin 4.2%, and free cash flow (~$241.1M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+113.9%) and Capex step-up ($98.8M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲8.0%
3,018.8
FY21→FY25CAGR +9.6%/yr
Net income ($M)—
127.9
one-off year: see footnoteCAGR +58.7%/yr
Free cash flow ($M)▲2.7%
241.1
capex stepped upCAGR +6.0%/yr
Diluted EPS—
0.22
FY21→FY25CAGR +33.1%/yr
What the receipts whisper · what a headline number hides
Share count
+113.9%
151.8mn → 324.8mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$98.8M
▲64% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
4¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 36.7% → 36.9%. Net margin 4.2% is above the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 3,195.7 | 3,018.8 | 2,794.0 | 2,393.6 | 2,212.3 | 2,093.7 | ▲8.0% | +9.6% |
Cost of revenue | 1,909.8 | 1,905.5 | 1,773.5 | 1,573.0 | 1,427.6 | 1,324.7 | ▲7.4% | +9.5% |
Gross profit | 1,285.9 | 1,113.3 | 1,020.4 | 820.6 | 784.7 | 769.0 | ▲9.1% | +9.7% |
Research & development | 187.8 | 193.8 | 196.6 | 167.8 | 200.0 | 201.8 | ▼1.4% | −1.0% |
Selling, general & admin | 573.7 | 526.8 | 476.4 | 429.7 | 399.7 | 365.5 | ▲10.6% | +9.6% |
Total operating expenses | 806.9 | 719.2 | 771.1 | 616.2 | 879.6 | 616.3 | ▼6.7% | +3.9% |
Operating incomefeeds ROC rank | 479.0 | 394.1 | 249.3 | 204.4 | −94.9 | 152.7 | ▲58.1% | +26.7% |
Other income, net | −257.5 | −254.9 | −304.3 | −244.6 | −153.2 | −121.3 | — | — |
Pretax income | 221.5 | 139.2 | −55.0 | −40.3 | −248.1 | 31.4 | — | +45.1% |
Income tax | 12.0 | 11.3 | 18.9 | 8.5 | 6.7 | 11.2 | ▼40.2% | +0.2% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 209.5 | 127.9 | −73.9 | −48.7 | −254.8 | 20.2 | — | +58.7% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.41 | 0.22 | −0.38 | −0.48 | −0.86 | 0.07 | — | +33.1% |
Diluted shares (mn) | 335.73 | 324.81 | 308.98 | 176.14 | 150.94 | 151.82 | ▲5.1% | +20.9% |
| Margins | ||||||||
Gross margin21st pct in Healthcare | 40.2% | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% | ▲0.4pp | +0.2pp |
Operating margin | 15.0% | 13.1% | 8.9% | 8.5% | −4.3% | 7.3% | ▲4.1pp | +5.8pp |
Net margin58th pct in Healthcare | 6.6% | 4.2% | −2.6% | −2.0% | −11.5% | 1.0% | ▲6.9pp | +3.3pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 36% vs a −3% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −21% vs a −3% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-27 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Amneal Pharmaceuticals' revenue last fiscal year?
Amneal Pharmaceuticals reported revenue of $3,018.8M in fiscal 2025, up 8.0% from fiscal 2024.
What was Amneal Pharmaceuticals' net income?
Amneal Pharmaceuticals reported net income of $127.9M in fiscal 2025, a net margin of 4.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

